Last reviewed · How we verify
Fosfomycin and imipenem
Fosfomycin and imipenem together provide dual antibiotic action by inhibiting bacterial cell wall synthesis through different mechanisms to treat serious infections.
Fosfomycin and imipenem together provide dual antibiotic action by inhibiting bacterial cell wall synthesis through different mechanisms to treat serious infections. Used for Serious bacterial infections caused by multidrug-resistant gram-negative organisms, Hospital-acquired and ventilator-associated pneumonia, Complicated urinary tract infections.
At a glance
| Generic name | Fosfomycin and imipenem |
|---|---|
| Sponsor | Juan A. Arnaiz |
| Drug class | Beta-lactam antibiotic combination |
| Target | Bacterial cell wall synthesis (MurA enzyme and penicillin-binding proteins) |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Fosfomycin inhibits MurA enzyme in peptidoglycan synthesis, while imipenem is a broad-spectrum beta-lactam that inhibits penicillin-binding proteins. This combination provides synergistic coverage against multidrug-resistant gram-negative and gram-positive bacteria, including some carbapenem-resistant organisms. The dual mechanism reduces the likelihood of resistance development.
Approved indications
- Serious bacterial infections caused by multidrug-resistant gram-negative organisms
- Hospital-acquired and ventilator-associated pneumonia
- Complicated urinary tract infections
Common side effects
- Nausea
- Diarrhea
- Headache
- Seizures (imipenem-related)
- Hypersensitivity reactions
Key clinical trials
- Pivmecillinam as Oral Step-Down Treatment for Escherichia Coli Febrile Urinary Tract Infection Versus Standard of Care (PHASE4)
- Patients Response to Early Switch To Oral:Osteomyelitis Study (EARLY_PHASE1)
- Fosfomycin Plus Imipenem for Treatment of Infective Endocarditis (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Fosfomycin and imipenem CI brief — competitive landscape report
- Fosfomycin and imipenem updates RSS · CI watch RSS
- Juan A. Arnaiz portfolio CI